Since the approval of Ipilimumab in the clinic, it has been used in combination with PD-1/PD-L1 blockade as a powerful way to treat a spectrum of different malignancies, including non-small cell lung carcinoma [103]. Here, CD274 is linked to non-small cell lung carcinoma.